The Role of Metabolic Syndrome in the Development of Colorectal Cancer

Objective. The aim of our study was to determine the role of metabolic syndrome (MetS) and its cluster in the development of colorectal cancer (CRC). Methods. 50 patients with the CRC diagnosis have been included in the study group (age 40-65 years). 50 conditionally healthy persons selected in the control group. The parameters determined during study fulfillment were: fasting and postprandial plasma glucose, fasting C-peptide and insulin, IGF and IGFBP3, HOMA indices, lipid spectrum, anthropometric parameters, blood pressure. MetS was defined by the IDF definition criteria. Obtained results were statistically treated by the soft SPSS23.0. Results. Obesity defined by body mass, BMI, and waist circumference was significantly more expressed in the study group (p<0.001). The levels of IGF and IGFBP3 in the study group were significantly differ compared to controls (p<0.001). Same pattern was obtained during study of carbohydrate homeostasis and insulin resistance. No significant difference was revealed between the values of blood pressure, creatinine and lipid metabolism (except HDL-C) in both groups. MetS were established for 37 patients (74%) in the study group, and 22 persons (44%) of the controls (Сhi2=9.21, p=0.002). Correlation analysis has shown significant association between the number of MetS features and CRC development (r=0.425, p<0.001). Conclusions. MetS, IGF-1, FPG, PPG, insulin resistance, and the degree of obesity was positively associated with CRC development; and insulin sensitivity and IGFBP3 was negatively correlated with CRC development. It should definitely be noted, the risk of CRC development was positively correlated with the number of MetS features. Therefore, first of all the disappear of these modifiable risk factors by lifestyle changes and subsequent measures plays the crucial role in the CRC prevention.